News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
725,654 Results
Type
Article (42914)
Company Profile (297)
Press Release (682442)
Multimedia
Podcasts (92)
Webinars (15)
Section
Business (210617)
Career Advice (2095)
Deals (36677)
Drug Delivery (108)
Drug Development (83173)
Employer Resources (175)
FDA (16660)
Job Trends (15444)
News (356479)
Policy (34005)
Tag
Academia (2600)
Accelerated approval (11)
Adcomms (23)
Allergies (104)
Alliances (51577)
ALS (115)
Alzheimer's disease (1494)
Antibody-drug conjugate (ADC) (164)
Approvals (16662)
Artificial intelligence (331)
Autoimmune disease (31)
Automation (19)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (131)
Biotechnology (188)
Bladder cancer (96)
Brain cancer (38)
Breast cancer (382)
Cancer (3002)
Cardiovascular disease (229)
Career advice (1758)
Career pathing (31)
CAR-T (192)
CDC (34)
Cell therapy (518)
Cervical cancer (23)
Clinical research (68555)
Collaboration (1079)
Company closure (3)
Compensation (716)
Complete response letters (30)
COVID-19 (2703)
CRISPR (64)
C-suite (363)
Cystic fibrosis (118)
Data (3145)
Decentralized trials (2)
Denatured (30)
Depression (66)
Diabetes (352)
Diagnostics (6520)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (147)
Drug pricing (138)
Drug shortages (31)
Duchenne muscular dystrophy (148)
Earnings (89357)
Editorial (44)
Employer branding (21)
Employer resources (151)
Events (116768)
Executive appointments (879)
FDA (18435)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (961)
Gene editing (140)
Generative AI (24)
Gene therapy (409)
GLP-1 (834)
Government (4646)
Grass and pollen (6)
Guidances (200)
Healthcare (19024)
HIV (40)
Huntington's disease (31)
IgA nephropathy (41)
Immunology and inflammation (163)
Immuno-oncology (10)
Indications (42)
Infectious disease (2883)
Inflammatory bowel disease (154)
Inflation Reduction Act (10)
Influenza (67)
Intellectual property (125)
Interviews (323)
IPO (16871)
IRA (53)
Job creations (4064)
Job search strategy (1494)
Kidney cancer (13)
Labor market (54)
Layoffs (525)
Leadership (20)
Legal (8402)
Liver cancer (80)
Longevity (12)
Lung cancer (417)
Lymphoma (218)
Machine learning (11)
Management (59)
Manufacturing (435)
MASH (97)
Medical device (13564)
Medtech (13570)
Mergers & acquisitions (20541)
Metabolic disorders (882)
Multiple sclerosis (99)
NASH (17)
Neurodegenerative disease (137)
Neuropsychiatric disorders (36)
Neuroscience (2220)
NextGen: Class of 2025 (6642)
Non-profit (4537)
Now hiring (49)
Obesity (445)
Opinion (243)
Ovarian cancer (102)
Pain (125)
Pancreatic cancer (129)
Parkinson's disease (190)
Partnered (22)
Patents (315)
Patient recruitment (178)
Peanut (53)
People (59744)
Pharmaceutical (91)
Pharmacy benefit managers (23)
Phase I (21257)
Phase II (30167)
Phase III (22595)
Pipeline (1720)
Policy (219)
Postmarket research (2655)
Preclinical (9072)
Press Release (68)
Prostate cancer (145)
Psychedelics (38)
Radiopharmaceuticals (259)
Rare diseases (494)
Real estate (6268)
Recruiting (68)
Regulatory (23623)
Reports (50)
Research institute (2376)
Resumes & cover letters (359)
Rett syndrome (9)
RNA editing (10)
RSV (52)
Schizophrenia (97)
Series A (162)
Series B (112)
Service/supplier (12)
Sickle cell disease (64)
Special edition (19)
Spinal muscular atrophy (151)
Sponsored (33)
Startups (3741)
State (2)
Stomach cancer (15)
Supply chain (79)
Tariffs (68)
The Weekly (60)
Vaccines (817)
Venture capital (56)
Weight loss (277)
Women's health (47)
Worklife (16)
Date
Today (125)
Last 7 days (494)
Last 30 days (1758)
Last 365 days (31494)
2025 (17980)
2024 (35771)
2023 (40633)
2022 (51799)
2021 (56329)
2020 (54791)
2019 (47398)
2018 (35770)
2017 (33140)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (786)
Alabama (63)
Alaska (7)
Arizona (251)
Arkansas (14)
Asia (41161)
Australia (6579)
California (7650)
Canada (2424)
China (706)
Colorado (325)
Connecticut (325)
Delaware (204)
Europe (88003)
Florida (1155)
Georgia (256)
Hawaii (2)
Idaho (60)
Illinois (667)
India (29)
Indiana (378)
Iowa (17)
Japan (242)
Kansas (110)
Kentucky (29)
Louisiana (15)
Maine (64)
Maryland (1053)
Massachusetts (5731)
Michigan (252)
Minnesota (466)
Mississippi (4)
Missouri (95)
Montana (28)
Nebraska (25)
Nevada (84)
New Hampshire (67)
New Jersey (2140)
New Mexico (29)
New York (2140)
North Carolina (1115)
North Dakota (8)
Northern California (3380)
Ohio (242)
Oklahoma (16)
Oregon (39)
Pennsylvania (1669)
Puerto Rico (17)
Rhode Island (37)
South America (1164)
South Carolina (35)
South Dakota (1)
Southern California (2872)
Tennessee (127)
Texas (1165)
United States (28461)
Utah (224)
Virginia (203)
Washington D.C. (72)
Washington State (654)
West Virginia (4)
Wisconsin (70)
725,654 Results for "alexion pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines
July 8, 2025
·
5 min read
Gene therapy
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M
The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR Pharmaceuticals for use in up to five of Alexion’s gene therapies.
July 9, 2025
·
1 min read
·
Dan Samorodnitsky
Earnings
AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma.
February 6, 2025
·
3 min read
·
Tristan Manalac
Business
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo ® Technology for Neurodegenerative Disease in Research Collaboration with Alexion.
March 19, 2024
·
4 min read
Press Releases
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.
July 3, 2025
·
7 min read
Business
Alexion Canada Appoints Karen Heim as New General Manager
Alexion Pharma Canada Corp., AstraZeneca’s Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.
April 2, 2024
·
3 min read
Press Releases
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
July 10, 2025
·
3 min read
Press Releases
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
July 16, 2025
·
5 min read
Press Releases
Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
July 16, 2025
·
5 min read
Press Releases
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
July 10, 2025
·
3 min read
1 of 72,566
Next
